ERBB2 and neoplasm: Other alterations are known to be bad prognostic factors in the RAS/BRAF wild type, but to our knowledge, they have not been described as being more prevalent in EOCRC patients, such as PIK3CA mutations (a known negative predictor of response to EGFR inhibitors in RAS wild-type tumors [28]) and HER2 status (its expression in the membrane of the tumor cells is associated with a shorter progression-free survival (PFS) to EGFR inhibitors) [29].